Europe
2026.11.19 00:47 GMT+8

Chinese scientist celebrated for 'East Meets West' breakthrough in cancer treatment

Updated 2026.11.19 00:47 GMT+8
Jeff Moody

Chen Zhu (left) said international cooperation had been central to his team's achievement. /CGTN

A Chinese scientist honoured with one of the world's most prestigious scientific awards has hailed his achievement as an 'East Meets West' success story, following a breakthrough that has transformed the treatment of a once-deadly form of blood cancer.

Chen Zhu, along with French scientists Anne Dejean and Hugues de Thé, has received the 2026 Shaw Prize in Life Science and Medicine for research that has turned Acute Promyelocytic Leukaemia (APL) from one of the deadliest forms of leukaemia into a highly treatable disease, with more than 90 percent of patients now surviving beyond five years.

Speaking at the award ceremony in Hong Kong, Chen said international cooperation had been central to the achievement.

"It is this borderless connection that empowers us to join forces in decoding the mysteries of life, bringing us closer to a healthier future," he said.

Chen giving an acceptance speech at the Shaw Prize award ceremony. /CGTN

Chen's interest in APL began in the early 1980s, when a diagnosis carried an 80 percent risk of death. Conventional treatments, including chemotherapy, offered limited hope.

But Chen and his colleagues began exploring an alternative approach, drawing inspiration from traditional Chinese philosophy.

"Could we overcome strength with gentleness? This is an idea rooted in Chinese philosophy," he said.

Their research led them to All-Trans Retinoic Acid, a derivative of vitamin A, which proved remarkably effective at targeting the abnormal leukaemia cells.

The potential was demonstrated in a five-year-old girl whose condition was considered terminal. Within weeks of receiving the treatment for Acute Promyelocytic Leukemia (APL), she had made a remarkable recovery and achieved complete remission.

The next breakthrough came through collaboration with French researchers and a separate discovery in Harbin, where scientists had been investigating the use of arsenic to treat the disease.

Combining arsenic trioxide with All-Trans Retinoic Acid produced what became known as the Shanghai Protocol. The treatment works by encouraging abnormal leukaemia cells to mature into normal blood cells, rather than simply destroying them.

The results have been extraordinary. A disease that was once considered virtually incurable now has a long-term survival rate of more than 90 percent. The protocol has since become the standard treatment for APL worldwide.

Chen hopes the same approach could eventually be applied to other cancers.

"What I hope is that we can extend this treatment approach to other cancers and help more cancer patients," he said.

Chen is the second Chinese national to receive the Shaw Prize Life Science and Medicine award.

The Shaw Prize, established in 2002, is often described as the 'Nobel Prize of the East'. Chen is the second Chinese national to receive its Life Science and Medicine award.

But he says recognition is not what drives scientific discovery.

"We don't conduct scientific research to win awards. Awards like these are merely by-products. The greatest wish of a scientist is to make a real difference to humanity."

For Chen and his international collaborators, the Shanghai Protocol is already proof of just how much can be achieved when scientific knowledge crosses borders.

Copyright © 

RELATED STORIES